NN2802 not checked

Novelty Nobility, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Healhty, Chronic Spontaneous Urticaria (CSU)
Main trialPhase 1/2
“NN2802 is a new product that is being developed for treating participants with CSU who remain symptomatic despite treatment with antihistamines. NN2802 is not yet an approved product and it can only be used in an experimental study like this one. The purpose of this study is to learn more about a new experimental drug called NN2802. NN2802 is an investigational fully human monoclonal antibody that inhibits c-Kit. c-Kit is involved in the survival, development, and activity of mast cells, which are important cells involved in allergic and inflammatory reactions. By inhibiting c-Kit, NN2802…”In the company’s words, NCT07930572 on ClinicalTrials.gov

Other drugs for Healhty

All 22 drugs for Healhty

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 31 Mar 2027 A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow NN2802

Following is part of Solo: you see every change to NN2802 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in